A pivotal European clinical trial has achieved a remarkable milestone in restoring central vision for people living with dry age-related macular degeneration (AMD) and geographic atrophy (GA).
The PRIMA trial, published in the New England Journal of Medicine, demonstrated that participants fitted with a new electronic eye implant were able to read letters, numbers, and words using prosthetic vision — a first for individuals who had lost their central sight.
Conducted across 17 sites in five countries, with Moorfields Eye Hospital serving as the UK site, this innovative research highlights the power of international collaboration and translational innovation in addressing unmet needs in retinal disease.
As Retina International continues to advocate for equitable access to emerging therapies, this breakthrough offers renewed hope for patients and families affected by vision loss worldwide.
Read the full story via NIHR Moorfields Clinical Research Facility here.
